arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

QuidelOrtho Corp

QDEL
$12.29 ▼ -4.05 (-24.76%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

QuidelOrtho Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $833.3M
Dividend Yield
Revenue Growth -1.9%
Op. Margin -33.7%
ROIC -20.3%
FCF / Share $-1.22
Trailing P/E
Price / Book 0.4x
FCF Yield
Debt / Equity 1.40
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.73B
↓ -1.9%
Net Income Profit after all expenses
$-1.13B
↑ +44.8%
Operating Margin Operating profit as % of sales
-33.7%
↑ +52.2% 7th
FCF / Share Free cash flow per share
$-1.22
↑ +26.6%
Long-Term Debt Long-term obligations
$2.70B
↑ +8.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
14
Financial Health
27
Cash Quality
25

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters